Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers.
Sign Up to like & getrecommendations! Published in 2019 at "Advances in experimental medicine and biology"
DOI: 10.1007/978-3-030-20301-6_10
Abstract: Trastuzumab represents the predominant therapy to target breast cancer subtype marked by HER2 amplification. It has been in use for two decades and its continued importance is underlined by recent FDA approvals of its biosimilar… read more here.
Keywords: trastuzumab resistance; breast; current updates; resistance her2 ... See more keywords
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers
Sign Up to like & getrecommendations! Published in 2021 at "Gastric Cancer"
DOI: 10.1007/s10120-021-01176-7
Abstract: To date, many efforts have been made to understand the resistance mechanism of trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancer. However, there is still a huge unmet medical need… read more here.
Keywords: positive cancers; trastuzumab resistance; her2 positive; resistance ... See more keywords
Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.
Sign Up to like & getrecommendations! Published in 2017 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2016.12.072
Abstract: Breast cancer is a complex disease with at least five different molecular subtypes identified. The breast tumor molecular subtypes guide stratification of patients for specific targeted therapy regimens and each subtype is associated with significantly… read more here.
Keywords: trastuzumab resistance; trastuzumab; s6k1; resistance ... See more keywords
WEE1 Inhibitor, AZD1775, Overcomes Trastuzumab Resistance by Targeting Cancer Stem-like Properties in HER2-positive Breast Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer letters"
DOI: 10.1016/j.canlet.2019.12.023
Abstract: Although trastuzumab has greatly improved the outcome of HER2-positive breast cancer, the emergence of resistance hampers its clinical benefits. Trastuzumab resistance is a multi-factorial consequence predominantly due to presence of cancer stem-like cells (CSCs). AZD1775,… read more here.
Keywords: cancer; cancer stem; trastuzumab resistance; breast cancer ... See more keywords
Label-free Quantitative Proteomics for Investigation of Signaling Pathways of GATA6 Regulating Trastuzumab Resistance in Gastric Cancer Cells
Sign Up to like & getrecommendations! Published in 2020 at "Chinese Journal of Analytical Chemistry"
DOI: 10.1016/s1872-2040(19)61215-6
Abstract: Abstract Trastuzumab resistance is one of the principal causes of failure in tumor chemotherapy. Previous studies showed that the DNA-binding activity of GATA6, a transcription factor, had a remarkable enhancement in trastuzumab resistant gastric cancer… read more here.
Keywords: trastuzumab resistance; gastric cancer; trastuzumab; gata6 ... See more keywords
Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.13758
Abstract: Currently, resistance to trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor, has become one major obstacle for improving the clinical outcome of patients with advanced HER2+ breast cancer. While cell behaviour can be… read more here.
Keywords: snhg14; trastuzumab resistance; breast cancer;
CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005063
Abstract: Background There was much hard work to study the trastuzumab resistance in HER2-positive gastric cancer (GC), but the information which would reveal this abstruse mechanism is little. In this study, we aimed to investigate the… read more here.
Keywords: her2; resistance; trastuzumab resistance; her2 positive ... See more keywords
Overexpression of GSE1 Related to Trastuzumab Resistance in Gastric Cancer Cells
Sign Up to like & getrecommendations! Published in 2021 at "BioMed Research International"
DOI: 10.1155/2021/8834923
Abstract: Gastric cancer is one of the most prevalent human cancers with poor prognosis. Trastuzumab is a well-used targeted drug for gastric cancer with HER2 amplification. Trastuzumab resistance restrains the clinical use of trastuzumab. In this… read more here.
Keywords: gastric cancer; trastuzumab resistance; cancer; cancer cells ... See more keywords
Disrupting Circadian Rhythm via the PER1–HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/0008-5472.can-21-1820
Abstract: In trastuzumab-resistant HER2-positive gastric cancer, glycolysis fluctuates with a circadian oscillation regulated by the BMAL1–CLOCK–PER1–HK2 axis, which can be disrupted with a metformin-based chronotherapy to overcome trastuzumab resistance. read more here.
Keywords: hk2 axis; per1 hk2; gastric cancer; trastuzumab resistance ... See more keywords
Abstract 2335: Disulfiram overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2/Akt signaling in HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-2335
Abstract: Although trastuzumab has shown a significant clinical benefit for HER2-positive breast cancers, responses are limited by the frequent emergence of resistance. Trastuzumab resistance is a multi-factorial phenomenon thought to arise from the presence of cancer… read more here.
Keywords: trastuzumab resistance; her2 positive; positive breast; cancer ... See more keywords
Abstract 3872: Targeting of YAP overcomes trastuzumab-resistance and promotes immune responses in HER2-positive cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3872
Abstract: Background: HER2 (Human epithelial growth factor receptor 2)-targeting therapies have been approved for patients with HER2-positive breast and gastric cancer and use have been attempted in various solid tumor types, including biliary tract cancer. However,… read more here.
Keywords: cell; yap; trastuzumab resistance; her2 positive ... See more keywords